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Abstract
Background: Levels of pentosidine (representative of advanced glycation end-products) in sera of patients with 
rheumatoid arthritis are increased when compared with sera of other diagnoses or healthy controls. These levels have 
been reported to correlate with clinical indices of rheumatoid arthritis activity and with laboratory markers of 
inflammation. The purpose of this study was to find out if these findings pertain to other advanced glycation end-
products.
Methods: We have developed two immunoassays based on new monoclonal antibodies to advanced glycation end-
products. Antibody 103-E3 reacts with an unidentified antigen, formed in the reaction of proteins with ribose, while 
antibody 8-C1 responds to Nε-(carboxyethyl)lysine. We have used these monoclonal antibodies to measure levels of 
advanced glycation end-products in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, 
osteoarthritis, and healthy controls. We calculated the correlations between advanced glycation end-product levels in 
rheumatoid arthritis sera and the Disease Activity Score 28 (DAS28), age, disease duration, CRP, anti-CCP, rheumatoid 
factor and treatment with corticosteroids, respectively.
Results: Levels of both glycation products were significantly higher in sera of patients with rheumatoid arthritis when 
compared with sera of patients with systemic lupus erythematosus, osteoarthritis, or the healthy controls. Neither the 
level of Nε-(carboxyethyl)lysine nor the level of the 103-E3 antigen in rheumatoid arthritis sera correlated with the 
DAS28-scored rheumatoid arthritis activity. The levels of both antigens in rheumatoid arthritis sera did not correlate 
with age, gender, corticosteroid treatment, or levels of CRP, anti-CCP antibodies, and rheumatoid factor in sera.
Conclusions: We report highly specific increases in the levels of two advanced glycation end-products in sera of 
patients with rheumatoid arthritis. This increase could be explained neither by rheumatoid arthritis activity nor by 
inflammation. We propose a working hypothesis that presumes the existence of a link between advanced glycation 
end-product formation and induction of autoimmunity.
Background
Nonenzymatic glycation of proteins consists of a series of
reactions between reducing carbohydrates and amino
groups of proteins. Labile Shiff bases that are formed in
the first step rearrange reversibly to the more stable Ama-
dori products. A plethora of permanent compounds,
formed from Amadori products in complex reaction
pathways, have been designated as advanced glycation
end-products (AGE). The currently-known AGE can be
classified into three major groups: non-cross-linking spe-
cies (e.g., Nε-(carboxymethyl)lysine, CML) [1], fluores-
cent cross-links (e.g., pentosidine) [2], and non-
fluorescent cross-linking species (e.g., glucosepan). Many
excellent reviews have described the reaction pathways of
AGE formation, their structure, relationship to aging and
disease, and other facets of the field [3]. * Correspondence: vili@revma.cz
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Thus far, all studies aimed at measuring AGE levels in
serum or plasma of patients with rheumatoid arthritis
(RA) have been limited to exclusively measuring pentosi-
dine using high-performance liquid chromatography
( H P L C )  [ 4 - 1 2 ] .  R A  s e r a  w e r e  c o m p a r e d  w i t h  s e r a  o f
h e a l t h y  c o n t r o l s  [ 4 , 7 , 8 ] ,  w i t h  s e r a  o f  p a t i e n t s  w i t h
os t eo a rt h ri t is  ( O A )  [ 6 ] ,  wi t h  s e r a  o f  pa t i e n ts  wi t h  sy s-
temic lupus erythematosus (SLE), or with sera of patients
with diabetes [5]. Pentosidine levels in plasma of RA
patients were compared with levels in plasma of patients
with OA, with levels in plasma of patients with diabetes,
and with levels in plasma of normal subjects [12]. Each of
these studies reported an increased mean level of pento-
sidine in RA serum/plasma. Furthermore, Takahashi et
al. [4] concluded that the level of pentosidine in sera of
RA patients reflects the activity of the disease, as the
serum level of pentosidine correlated with clinical indices
of RA activity, as well as with levels of serum markers of
inflammation (CRP, ESR) and the level of rheumatoid fac-
tor (RF).
AGE are immunogenic; the preparation of polyclonal
antibodies to pentosidine was announced by two groups
within the past decade [13,14]. The first monoclonal anti-
body (mAb) to AGE, designated 6D12, was prepared in
1991 [15], but the corresponding antigen was identified
only five years later as CML [1]. Later, the authors
reported cross-reactivity of this mAb to Nε-(carboxy-
ethyl)lysine (CEL) [16]. The development of the first spe-
cific mAb to CEL was reported in 2008 [17]. MAb to
pentosidine is also commercially available (Cosmo Bio
Co, Tokyo, Japan); however, we are not aware of any pub-
lished information regarding its use in enzyme immuno-
assays.
We wished to investigate whether the reported increase
of pentosidine levels in RA sera, and the positive correla-
tion between pentosidine serum level and RA activity,
a l s o  p e r t a i n  t o  o t h e r  A G E  m o l e c u l e s .  I n  c o n t r a s t  t o
HPLC, immunoassays are potentially more useful in rou-
tine laboratory practice. Thus, we decided to develop
original immunoassays based on new mAbs to AGE.
Methods
Preparation of glycated antigens
Antigens were prepared according to the following three
procedures.
Procedure A: reaction of protein carriers (BSA, bovine
crystallin, porcine thyroglobulin, ovalbumin) with ribose.
Proteins (50 mg/ml) were dissolved in 0.25 M phosphate
buffer (pH 7.8) containing 0.5 M ribose. After addition of
2 drops of toluene, the samples were incubated for 6
weeks at 37°C. All samples were dialyzed extensively
against phosphate-buffered saline (PBS) after 6 weeks to
remove free sugar, then incubated again at 37°C for
another 2 weeks to allow formed glycation products to
ripen.
Procedure B: reaction of protein carriers with glyoxylic
acid in the presence of sodium cyanoborohydride [18].
This reaction generates mainly CML.
Procedure C: reaction of protein carriers with pyruvate
in the presence of sodium cyanoborohydride [19]. This
reaction generates mainly CEL.
Preparation and selection of monoclonal antibodies
Splenocytes of Balb/c mice immunized with particular
antigens were electrofused [20] with cells from the
myeloma line Sp2/0. Hybridoma supernatants were
screened over several subsequent rounds to gradually
focus the selection. 1) Screening against the immunizing
hapten, bound to a different protein carrier. 2) Screening
against all non-modified protein carriers (BSA, crystallin,
thyroglobulin, ovalbumin) and these same protein carri-
ers modified by glycation ("ribosylation," change of lysine
to CML or CEL), coated to a solid phase. 3) Selected pairs
of glycated carriers were tested for the ability to mutually
inhibit binding of corresponding antibodies to coated
antigens. In this step, we compared the affinity of anti-
bodies for antigens presented either in solid or liquid
phase. The requirement of an antibody with similar affin-
ity for antigen presented in solid or liquid phases is neces-
sitated by its intended use in an inhibition enzyme-linked
immuno-sorbent assay (ELISA) depicted in the flow chart
shown in Figure 1. The interaction of an antigen with an
antibody that occurs in an inhibition mixture established
on a low-binding plate (left side of the flow chart) takes
place in liquid phase; the interaction of the antigen with
free antibody, that occurs after transferring the inhibition
mixture onto a high-binding plate coated with the antigen
(right side of the flow chart), takes place in solid phase. It
is important that antigen-antibody complexes that
formed in the liquid phase should remain stable during
this latter step. 4) Concentrations of antigens used for
coating plates and dilutions of culture media containing
particular antibodies were optimized by titration.
Selected conditions were used to test the inhibition of
mAb binding to corresponding antigens coated to plates
by diluted human sera. This test directly addressed the
presence of measurable hapten levels in human serum
(i.e., use of the corresponding mAb for analysis of human
sera by inhibition ELISA).
Two mAbs were selected for further work: 103-E3
(unidentified antigen formed in the reaction of proteins
with ribose), and 8-C1 (CEL). Both these mAbs are IgG1,
kappa. These mAbs were isolated from culture media on
Protein G, labeled with biotin, and used to develop inhi-
bition ELISAs.Vytášek et al. BMC Musculoskeletal Disorders 2010, 11:83
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Development of ELISAs and their characterization
We have developed an indirect inhibition ELISA for use
with our mAbs. The steps for this procedure are shown in
Figure 1.
We have used an AGE-modified high-molecular-weight
protein as a temporal working standard, expressing
results as its weight equivalents. Standards were either
BSA glycated with ribose (Rib-BSA) for mAb 103-E3, or
CEL-crystallin for mAb 8-C1. Either the same (Rib-BSA
for mAb 103-E3) or the next from the set of proteins
modified with corresponding AGE (CEL-ovalbumin for
mAb 8-C1) was used as an antigen for coating high-bind-
ing plates. Maximum amplification of the signal was
achieved by using a combination of biotin-labeled mAb
and ultra-sensitive streptavidin-peroxidase polymer for
detection.
It was necessary to use extreme dilution of antibodies
in the inhibition mixture to achieve the required sensitiv-
ity in both assays, as the antigen concentrations in the
samples (sera) are very low. Therefore, we blocked not
only the coated MaxiSorp plates used for ELISA, but also
the low-binding plates used for incubation of the inhibi-
tion mixture. We used synthetic polymer polyvinylpyr-
rolidone (PVP) [21] for blocking the low-binding plates,
and we also added it to all solutions used for dilution of
antibodies and standards. Results can be affected, as any
protein added to the inhibition mixture can hypotheti-
cally bind the antibody due to its natural content of AGE.
Figure 1 Flow chart showing steps of the indirect inhibition ELISA.
Low-binding plate for inhibition step
Dilute samples and prepare titration of 
standards 
  
Mix the sample/standards with a constant 
amount of a labeled antibody
  
Incubate until antigen-antibody binding 
equilibrium is reached
  
Transfer to coated and blocked high-
binding  plate     
High-binding plate for ELISA
Coat wells with the antigen
  
Block coated wells
  
  
Incubate to allow binding of antibody left 
free in the inhibition mixture to the antigen 
coated to wells
  
Remove the inhibition mixture with the 
antibody bound to the antigen in the 
sample
  
Add a reagent (streptavidin-enzyme for 
antibody labeled with biotin) to detect 
labeled antibody bound to the antigen 
coated to wells
  
Add a chromogenic substrate for the 
enzyme
  
Read color which is inversely proportional 
to the content of the antigen in the sample Vytášek et al. BMC Musculoskeletal Disorders 2010, 11:83
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Coated MaxiSorp plates were blocked with BSA; at this
stage, the results can no longer be affected by any possi-
ble natural content of AGE in albumin.
Both ELISAs are very sensitive; titration curves of sera
diluted 20×, 40×, and 80× in the inhibition mixture were
practically parallel with the 4-parameter calibration curve
that was obtained by titration of standards. Representa-
tive examples of both calibration curves are shown in Fig-
ure 2. Intra-assay variability of both ELISAs was
approximately 5%. Inter-assay variability was higher (10-
20%), possibly due to an operator change during the
course of the study. Sera sets that should be directly com-
pared were measured, if possible, on one plate, to avoid
possible bias from high inter-assay variability. For larger
sets that had to be accommodated on several plates,
coded sera samples of all diagnoses were grouped, and
then the order of all samples was randomized. Results
measured on different plates were always normalized to
the mean of the octuplicate control (pooled) serum that
was included on every plate. Results were taken from one
of at least two independent measurements, performed at
least one week apart.
Labeled mAbs stored at 4°C, and standards divided into
small aliquots and stored at -20°C are stable for a mini-
mum of several months. Serum samples are stable for one
week if stored unfrozen at 4°C; frozen serum samples (-
70°C) are stable for a minimum of 10 freeze/thaw cycles.
However, levels measured in the same sample differ
depending on the storage method. Following the first
freeze/thaw cycle, levels measured in frozen sera were
approximately 10% higher than samples that were never
frozen. This change of approximately 10% remained unal-
tered during further freeze/thaw cycles. This phenome-
non can be explained, in our opinion, by partial
denaturation of serum proteins, leading to increased
epitope accessibility for the antibody.
Since pentosidine prevails among species generated
during in vitro glycation of proteins with ribose [18], we
measured the level of 103-E3 antigen in a collection of
sera with a known concentration of pentosidine deter-
mined by HPLC [8]. However, we found no correlation
between the concentration of 103-E3 antigen measured
with ELISA and the concentration of pentosidine (Braun
and Vilim, unpublished results). This observation indi-
cates that ribose-derived 103-E3 antigen is different from
pentosidine. Since pentosidine is a product of glycoxida-
tion, this conclusion is consistent with our addition of a
drop of toluene to the ribosylation mixture to avoid bac-
terial contamination. Thus, conditions were created that
preferred simple glycation over glycoxidation by blocking
oxygen access to the glycation mixture.
Definitive protocol for inhibition ELISA with monoclonal 
antibody 103-E3
In-house prepared reagents
BSA modified with ribose (Rib-BSA); mAb 103-E3
labeled with biotin (EZ-LINK™ NHS-LC-biotin, 21336,
Pierce, Rockford, IL, USA) to molar ratio of IgG:biotin
approximately 1:50 (b-103-E3).
Plate coating
"High-binding" MaxiSorp plates (F96, 442404, Nunc A/S,
Roskilde, Denmark) were coated by Rib-BSA, 5 μg/ml in
Figure 2 Representative examples of calibration curves of inhibition ELISAs with mAbs 8-C1 and 103-E3. Duplicate calibration curves were 
established on one plate.
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50 mM carbonate/bicarbonate buffer (pH 9.2), 100 μl/
well. After addition of the antigen, the plate was covered
with plate-sealing tape, incubated on an orbital shaker at
room temperature (RT) for 2 hours, then stored at 4°C
overnight.
Inhibition step (Day 1)
"Low-binding" plates for the inhibition step (either non-
treated polypropylene U96 PP MicroWell Plates, 267385,
Nunc, or non-treated polystyrene F96 MicroWell Plates,
269620, Nunc) were blocked by 1% PVP (PVP40, Sigma-
Aldrich s.r.o., Praha, Czech Republic) in PBS (300 μl/well,
2 h RT on the orbital shaker). Blocked low-binding plates
were immediately washed 3× with PBS/0.05% Tween 20
(TPBS) and used to set up an inhibition mixture. Stan-
dard (Rib-BSA) was diluted as well as titrated in PBS/1%
PVP/0.02% sodium azide (PBS/PVP/azide); titration
started at 8 μg/ml, and the resulting volume after titration
was 70 μl/well. Sera were diluted 10× in PBS/PVP/azide
and assayed in duplicate. 70 μl b-103-E3 diluted 100,000×
in PBS/PVP/azide were added to each well containing 70
μl of standard or diluted serum. The resulting dilutions of
reagents in the inhibition mixture were as follows: stan-
dard (Rib-BSA) titrated to concentrations of 4, 2, 1, 0.5,
0.25, 0.125, 0.0625, and 0.03125 μg/ml; sera diluted 20×;
b-103-E3 diluted 200,000× (approximately 10 ng/ml).
Final volume of the inhibition mixture was 140 μl/well.
The low-binding plate with the inhibition mixture was
covered with plate-sealing tape, incubated on the orbital
shaker at RT for 2 hours, and stored at 4°C overnight.
ELISA (Day 2)
The coated MaxiSorp plate was blocked (5% BSA in PBS,
120 μl/well) for 2 h at RT on the orbital shaker, and
washed 5× with TPBS. 100 μl of the inhibition mixture
was transferred to the coated and blocked MaxiSorp plate
and incubated on the orbital shaker at RT for 2 hours.
The plate was washed 5× with TPBS, and 100 μl of
Streptavidin-Peroxidase Polymer (S2438, Sigma-Aldrich),
diluted 2000× in PBS/1% PVP, was placed into the wells
for 30 min at RT on the orbital shaker. Another wash 5×
with TPBS followed, and 100 μl of peroxidase substrate
(0.05% o-phenylenedamine dihydrochloride + H2O2, in
citrate/phosphate buffer pH 5.0) were placed into the
wells. Color development was stopped by the addition of
1 M H2SO4, 100 μl/well. Absorbance was measured at 492
nm. Concentration of the antigen in the samples was cal-
culated using the 4-parameter calibration curve and
expressed as equivalents of Rib-BSA preparation.
Inhibition ELISA with monoclonal antibody 8-C1
In-house prepared reagents
Ovalbumin, containing a subset of lysine residues modi-
fied to CEL, used as a plate coating antigen; crystallin,
with a subset of lysine residues modified to CEL, used as
a standard; mAb 8-C1, labeled with biotin (EZ-LINK™
NHS-LC-biotin, Pierce) to molar ratio of IgG:biotin
approximately 1:50 (b-8-C1).
The assay was developed and performed according to
the same protocol as ELISA with mAb 103-E3; these two
methods differ only with respect to the in-house pre-
pared reagents and their dilutions.
Subjects
This study included 45 RA patients, 40 patients with SLE,
48 patients with OA of the knee, and 51 healthy volun-
teers (HC). Informed consent for the study was given by
all subjects, and the study was approved by the local eth-
ics committee. Basic demographic, clinical and labora-
t o r y  d a t a  c o r r e s p o n d i n g  t o  d a t e  o f  s e r a  c o l l e c t i o n  a r e
summarized for all cohorts in Table 1. Clinical data
include Disease Activity Score 28 (DAS28) [22] for RA
patients, Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) [23] for SLE patients, and grading
according to Kellgren and Lawrence (K/L grade) [24] for
OA patients. All RA patients were treated with anti-TNF-
α therapy (infliximab) in combination with methotrexate
(MTX). Infliximab was administered by intravenous infu-
sion at a dosage of 3 mg/kg every 8 weeks; MTX was
administered at a constant dosage of 10-20 mg/week. In
addition, 40/45 RA patients (89%) received a constant
dosage of glucocorticoids (either methylprednisolone 4-
10 mg/day or prednisolone 2.5-10 mg/day or every other
day). Sera were collected during the first year of treat -
ment with infliximab; prior to serum collection, each RA
patient received at least 4 infliximab infusions. This RA
patient cohort was chosen for the treatment with inflix-
imab due to extremely high disease activity, and because
they failed to respond to previous treatment. The cohort
also included a high proportion of non-respondents to
the infliximab therapy. 87% of RA patients were RF posi-
tive, and 69% were anti-CCP positive.
Laboratory methods
Sera were stored at -70°C until used. Levels of the follow-
ing markers were determined using commercially-avail-
able kits, according to the manufacturers' protocol: high-
sensitive CRP (CRP Latex, Olympus-Diagnostic, Olym-
pus Czech Group, Praha, Czech Republic), anti-cyclic cit-
rullinated peptide antibodies (Anti-CCP ELISA, Euro-
Diagnostica AB, Malmö, Sweden), and rheumatoid factor
(Particle Agglutination Test Serodia-RA, Fujirebio Inc.,
Tokyo, Japan).
Statistical analysis
Sera levels of AGE of analyzed cohorts were compared
using nonparametric tests; two cohorts were compared
by the Mann-Whitney test, and three cohorts were com-
pared by the Kruskal-Wallis test, followed by mutual
comparison of all groups by Dunn's post test. The value
1.0 was assigned to samples with the antigen level belowVytášek et al. BMC Musculoskeletal Disorders 2010, 11:83
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the limit of ELISA detection, to allow their inclusion in
statistical analyses with nonparametric tests. The rela-
tionship between two variables was estimated by Spear-
man's nonparametric correlation. The proportion of
males in all four cohorts was evaluated by chi-square test.
P values lower then 0.05 were considered to be signifi-
cant. Statistical analyses were performed using GraphPad
Prism version 4.00 for Windows (GraphPad Software,
San Diego, CA, USA).
Results
AGE levels in RA sera
We observed accumulation of both measured glycation
products (CEL and antigen binding to mAb 103-E3) in
sera of RA patients (Figure 3). The difference was highly
significant (P < 0.0001) when all three cohorts shown in
Figure 3 (RA, SLE, HC) were simultaneously compared.
The significant increase of AGE levels in RA sera versus
SLE sera, as well as versus HC sera, was confirmed (P <
0.001) by Dunn's post-test. Levels of both antigens in SLE
and HC sera did not differ. Means ± standard deviation
(SD) determined for all three cohorts and both antigens
are shown in Table 2. OA joined the list of diagnoses with
significantly lower serum levels of antigenic AGE when
compared with RA. OA sera were analyzed together with
repeated analysis of RA sera, enabling direct comparison
of both diagnoses (Figure 4); the difference was again
highly significant (P < 0.0001). Means ± SD appear in
Table 2.
Correlation of AGE levels in RA sera with clinical and 
laboratory data
Neither the levels of CEL nor the levels of 103-E3 antigen
i n  R A  s e r a  c o r r e l a t e d  w i t h  R A  a c t i v i t y  m e a s u r e d  b y
DAS28 score (Table 3). Levels of both antigens in RA sera
did not correlate with age, gender, treatment with corti-
costeroids, levels of CRP, anti-CCP antibodies, or RF in
sera (Table 3). The only significant correlation we
observed (P = 0.0317) was the negative correlation
between disease duration and concentration of 103-E3
antigen (Table 3). This correlation should not be consid-
ered significant, as we report the results of testing 7 inde-
pendent null hypotheses for each ELISA; applying the
Bonferroni correction for multiple hypothesis testing, a
P-value accepted as significant at the 5% level should be
less then 0.0073. However, also the P-value of the nega-
tive correlation between disease duration and CEL con-
centration was the lowest P-value calculated, although it
did not reach statistical significance. Decrease of appar-
ent AGE levels in RA sera with disease duration would
make sense if, for example, autoantibodies reacting to
AGE and interfering in assays gradually accumulated in
Table 1: Major demographic, clinical, and laboratory characteristics of analyzed cohorts.
RA SLE OA HC
N (males/females) 45 (12/33) 40 (4/36)¶ 48 (13/25) 51 (18/33)
age (years) 54 ± 13** 41 ± 13*** 66 ± 10* 44 ± 15
disease duration 
(years)
13 ± 7 8 ± 8 8 ± 7
DAS28 4.7 ± 1.2
SLEDAI 11.8 ± 6.7
K/L grade
(I/II/III/IV)
2.6 ± 0.8
(2/22/17/7)
CRP (mg/l) 15.0 ± 19.2† 4.0 ± 3.8 4.0 ± 3.3
ESR (mm/h) 28 ± 21
RA - rheumatoid arthritis; SLE - systemic lupus erythematosus; OA - osteoarthritis; HC - healthy volunteers (controls). Continuous 
characteristics are expressed as mean ± SD. ¶The proportion males/females in cohort of SLE patients was significantly different from other 
three cohorts that did not significantly differ from each other. *The mean age of OA patients was significantly higher than the mean age of 
all three other cohorts; **the mean age of RA patients was significantly lower then the mean age of OA patients but significantly higher than 
the mean age of subjects in SLE and HC cohorts; *** the mean age of subjects in SLE and HC cohorts did not significantly differ. †The mean 
level of CRP in sera of RA patients was significantly higher than the mean level of CRP in sera of patients with SLE and OA.Vytášek et al. BMC Musculoskeletal Disorders 2010, 11:83
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RA sera during the course of the disease. Our preliminary
data (Vilim and Vytášek, unpublished data) suggest that
this hypothesis may be correct.
Discussion
In the current study, we have extended the data on AGE
in sera of RA patients. We determined AGE levels with
ELISA, rather than the HPLC that has been used exclu-
sively thus far. Additionally, we measured in sera two new
AGE molecules, instead of only measuring pentosidine.
To this purpose, we employed original in-house ELISAs
with two new mAbs to AGE. W e report the significant
increase in mean levels of corresponding AGE in sera of
RA patients.
Our results do not support the initially-published con-
clusion that AGE serum concentration correlates with
RA activity and concentrations of inflammation markers.
With the exception of disease duration, we did not iden-
tify associations of AGE levels with any RA attribute or
inflammation marker included in this study. Indeed,
upon examination of all published studies, correlation
between serum/plasma pentosidine and laboratory mark-
ers/clinical indices appears equivocal. For example, four
[6,9,10,12] of six studies confirmed statistically-signifi-
cant positive correlations between serum pentosidine and
CRP, but two [8,11] did not. Correlation between DAS28
and serum pentosidine was reproduced only in one study
[9] of four [8-11].
Table 2: Levels of CEL and antigen binding to mAb 103-E3 determined in all investigated cohorts.
RA versus SLE versus HC RA versus OA
RA SLE HC RA OA
Equivalents of CEL-crystallin
(μg/ml)
4.87 ±1.989 2.92 ±1.140 2.83 ±1.437 5.413 ± 2.631 2.994 ± 2.023
Equivalents of Rib-BSA 
(μg/ml)
3.306 ± 0.755 2.287 ± 0.675 2.111 ± 0.620 2.993 ± 0.668 1.873 ± 0.692
RA - rheumatoid arthritis; SLE - systemic lupus erythematosus; OA - osteoarthritis; HC - healthy volunteers (controls). Results are expressed as 
means ± standard deviation of equivalents of CEL-crystallin or Rib-BSA. Samples with the level of measured antigen below the detection limit 
of the assay were not included in the calculation; these were 1 RA, 5 SLE, and 7 HC samples, respectively, assayed for CEL in the part "RA versus 
SLE versus HC", and 19 OA samples assayed for CEL and 1 OA sample assayed for 103-E3 antigen in the part "RA versus OA".
Figure 3 AGE levels in sera of patients with rheumatoid arthritis and systemic lupus erythematosus, and controls. The levels of Nε-(carboxy-
ethyl)lysine (expressed as equivalents of CEL-crystallin) and 103-E3 antigen (expressed as equivalents of Rib-BSA) were measured in sera of patients 
with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and sera of healthy volunteers as controls (HC). The value 1.0 was assigned to 
samples with CEL levels of below the limit of ELISA detection with mAb 8-C1, to allow their inclusion in statistical analyses with nonparametric tests. 
Lines represent medians.
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In fact, this discrepancy among correlation analyses is
not surprising. Perhaps a fluctuation in mean blood glu-
cose (reducing sugars) levels within the time interval that
precedes serum collection may be the reason. Glycated
proteins in the blood are considered to provide an inte-
grated measure of blood glucose over a scale of days to
weeks, as they reflect the mean blood glucose level over a
period of their half-life [25]. Since reactions that form
AGE are not reversible, AGE slowly accumulate over the
lifetime of a protein, and the extent of modification is
thus a function of protein turnover. Presuming the ran-
dom targeting of accessible lysines of serum proteins for
glycation, the most modifications can be expected to be
present on the most abundant serum protein, serum
albumin. Indeed, the extent of albumin glycation
accounts for more than half of total plasma protein glyca-
tion [26]; of the 59 lysines present in human serum albu-
min, 31 have been found to be glycated in vivo [27].
Figure 4 AGE levels in sera of patients with rheumatoid arthritis and osteoarthritis. The level of Nε-(carboxyethyl)lysine (expressed as equiva-
lents of CEL-crystallin) and the level of 103-E3 antigen (expressed as equivalents of Rib-BSA) were measured in sera of patients with rheumatoid ar-
thritis (RA) and osteoarthritis (OA). The value 1.0 was assigned to samples with CEL levels below the limit of detection of ELISA with mAb 8-C1, to allow 
their inclusion in statistical analyses with nonparametric test. Lines represent medians.
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Table 3: Correlation between serum AGE levels and selected characteristics of patients with rheumatoid arthritis
CEL 103-E3 antigen
Spearman r P Spearman r P
DAS28 -0.0861 0.5783 -0.1032 0.5051
Age -0.1367 0.3879 -0.0940 0.5485
Disease duration -0.1945 0.2114 -0.3244 0.0317
CRP -0.1204 0.4420 0.0971 0.5306
anti-CCP titer -0.0974 0.5407 -0.1170 0.4604
RF titer -0.1173 0.4651 0.0191 0.9043
corticosteroid dose 0.0472 0.7813 0.1884 0.2574Vytášek et al. BMC Musculoskeletal Disorders 2010, 11:83
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Specific albumin glycation depends on its half-life, and
with an average life span of approximately 20 days, gly-
cated albumin is considered to be an indicator of mid-
term (2-3 weeks prior to serum sampling) glycemic con-
trol [28]. Hence, the correct approach for assessing corre-
lation between serum AGE levels and RA activity would
be to assess the correlation between a specific protein
modification level and a synovitis, present in all joints in
the body during the interval of this protein's half-life.
Similarly, when calculating the correlation between
serum AGE levels and laboratory inflammation markers,
half-lives of a selected glycated protein and a selected
i n f l a m m a t i o n  m a r k e r  i n  s e r u m  s h o u l d  b e  c o m p a r a b l e ,
unless there is evidence that the level of the selected
marker was stable over the given time interval. Accord-
ingly, we also believe that a hypothetical age effect on the
AGE levels we have measured is improbable. While the
gradual accumulation of AGE with age on long-lived pro-
teins is well-documented [29], in serum all proteins have
short- to mid-term half-lives, and thus glycation would be
affected by their actual fluctuations during this time
interval, rather then by patient age. While the mean age
of subjects in the RA cohort may be a cause of concern
from the viewpoint of the effect of age, being higher than
the mean age in the SLE and HC cohorts, the mean age of
s u b j e c t s  i n  O A  c o h o r t  w a s  h i g h e r  c o m p a r e d  w i t h  RA
cohort.
There is no doubt that AGE levels in RA sera/plasma
are increased, as this increase has been reported for pen-
tosidine in six papers by five independent groups. In fact,
RA is the disease with the highest mean level of pentosi-
dine in serum/plasma of all diseases investigated so far ,
even higher than the mean level found in sera/plasma of
diabetic patients [5,12]. This last finding was corrobo-
rated for both AGE measured here (Vilim and Vytášek,
unpublished results). All patients in our RA cohort were
treated with MTX and with infliximab. Both of these
treatments have been independently shown to reduce
levels of pentosidine in RA sera [9,10], and thus the levels
o f  A G E  w e  h a v e  m e a s u r e d  h e r e  w o u l d  l i k e l y  b e  e v e n
higher in untreated RA patients.
What is the participation of the receptor for advanced
glycation end-products (RAGE)? AGE, via RAGE signal-
ing, amplify the inflammatory response [30], and in this
way likely play a role in sustaining chronic inflammation.
It has to be borne in mind, however, that RAGE binds
several discrete families of structurally dissimilar ligands
in addition to AGE. Furthermore, the AGE designation
also involves a diverse class of heterogeneous com-
pounds, and not all AGE activate RAGE. More RAGE
ligands likely exist within the AGE group, but only CML
has been unambiguously demonstrated to be a RAGE
ligand so far [31]. Pentosidine, on the other hand, does
not seem to bind RAGE [18]. Although accumulation of
AGE generally can contribute to the perpetuation of
chronic inflammation in RA synovia, the cause of their
accumulation remains obscure.
Oxidative stress resulting in the generation of free radi-
cals in inflamed joints has been suggested to cause
increased formation of AGE in RA. This hypothesis
seems to be in agreement with our observation that the
mean DAS28 value in our RA patient cohort at the time
of sera collection still indicated increased disease activity.
Additionally, the mean level of CRP in RA sera was also
significantly increased compared with SLE and OA sera.
However, CRP and AGE levels in RA sera did not corre-
late and seemed to be independent of each other (Table 3)
while, as expected, CRP levels correlated significantly
with DAS28 (data not shown).
An alternative hypothesis of autoimmunity, currently
gaining experimental support, would also explain the
available data. We propose to look for an opposite causal-
ity; rather than RA causing increased glycation, perhaps
individuals prone to nonenzymatic glycation of proteins
(for whatever reason) may be more likely to develop RA.
This working hypothesis is plausible and attractive, since
glycation forms new antigenic determinants on proteins.
This type of connection has been already demonstrated
for a different class of posttranslational protein modifica-
tion, represented by conversion of arginine to citrulline,
in a large subset of RA patients [32]. RA is an extremely
complex disease, with an etiology involving the interplay
of (at least) genetic predisposition, environmental factors,
and immunity to self molecules made immunogenic by
posttranslational modification [33]. Recent reviews con-
tain many examples of different posttranslational modifi-
cations within target proteins leading to the breaking of
immunological tolerance and induction of autoimmunity
[34-37]. The process would ultimately lead to the devel-
opment of "genuine" autoantibodies by epitope spreading.
It has long been known that glycosylation patterns of
the IgG constant region are skewed toward less galactosy-
lated variants in patients with RA [38]. It was hypothe-
sized that incomplete galactosylation may be responsible
for the induction of RF in RA [39] but the support for this
hypothesis is weak and indirect [40,41]. However, RA sera
contain autoantibodies against agalactosyl IgG [42,43].
Another group reported detection of autoantibodies to
IgG that has been modified by binding AGE in sera of RA
patients [44,45]. Hence, abnormal glycation of IgG in
patients with RA was already related to induction of
autoantibodies. We believe that the possibility this effect
pertains also other serum proteins merits experimental
testing. The antibodies we have developed could become
useful tools in this effort.Vytášek et al. BMC Musculoskeletal Disorders 2010, 11:83
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Conclusion
We report the highly specific increase of two advanced
glycation end-products in sera of patients with rheuma-
toid arthritis. This increase could be explained neither by
RA activity nor by inflammation. We propose a working
hypothesis that presumes the existence of a link between
AGE formation and the induction of autoimmunity.
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